IRVINE, Calif. – Oventus Medical has reported interim financial results for the six months ended Dec. 31, 2021, including $554,000 in revenue. The company, which makes the O2Vent oral device to treat ...

Oventus Medical Ltd (ASX:OVN) is pleased to announce the Canadian launch of the O2Vent (R) Optima device which treats both the potentially fatal condition, obstructive sleep apnoea and snoring. The ...

Brisbane, July 12, 2017 AEST (ABN Newswire) - Australian medical device company, Oventus Medical Ltd. (ASX:OVN) has received FDA 510k clearance for its O2Vent W device, an oral appliance intended to ...

Brisbane, May 5, 2017 - (ABN Newswire) - Australian medical device company Oventus Medical Ltd. (ASX:OVN), has lodged an FDA 510k submission for its O2Vent W device - an oral appliance intended to ...

Receives FDA Clearance for the O2Vent W Brisbane, July 12, 2017 AEST (ABN Newswire) - Australian medical device company, Oventus Medical Ltd. (ASX:OVN) has received FDA 510k clearance for its O2Vent W ...

Medical device company Oventus Medical (ASX: OVN) has confirmed its sleep treatment platform will be included in a range of obstructive sleep apnoea (OSA) treatment solutions being sold by Aeroflow ...

Mel Bridges-chaired Oventus Medical’s (ASX: OVN) newly developed ExVent PEEP valve has successfully treated obstructive sleep apnoea patients in conjunction with the company’s existing O2Vent ...

Australia-based medical device company Oventus Medical will unveil its O2Vent flagship product in the US later this month to treat snoring and sleep apnoea. Cleared by the US Food and Drug ...

Oventus Medical Ltd (ASX:OVN) is pleased to announce the launch of the O2Vent(R) Optima device in Australia, an important addition to the Company's sleep treatment platform. Key points: - New Oventus ...

Oventus Medical Ltd (ASX:OVN) is pleased to announce the Canadian launch of the O2Vent(R) Optima device which treats both the potentially fatal condition, obstructive sleep apnoea (OSA) and snoring.